Galderma v. Dr. Reddy's Laboratories: Tetracycline Patent Case Dismissed Without Prejudice
Galderma Laboratories and TCD Royalty Sub, LP filed suit against Dr. Reddy's Laboratories in Delaware over two patents covering once-daily tetracycline formulations. The parties reached an agreement within 67 days, and all claims were dismissed without prejudice — leaving the door open to future proceedings.
Pharma patent battle over once-daily tetracyclines ends in 67-day dismissal
On June 30, 2023, Galderma Laboratories, L.P. and TCD Royalty Sub, LP filed an infringement action in the U.S. District Court for the District of Delaware against Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. The complaint asserted two patents — US7749532B2 and US8206740B2 — directed to once-daily formulations of tetracyclines, a class of antibiotics with established pharmaceutical applications including dermatology.
The case was terminated on September 5, 2023 — just 67 days after filing. The recorded basis of termination is 'Dismissed without Prejudice.' The docket order states that the parties stipulated under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) to dismiss all claims, counterclaims, and affirmative defenses without prejudice, without costs, disbursements, or attorneys' fees, pursuant to an agreement dated September 1, 2023. The court retained jurisdiction to enforce and resolve any disputes arising under that agreement.
The 67-day resolution timeline is notably compressed for a pharmaceutical patent dispute of this nature, suggesting the parties had pre-existing discussions or reached commercial alignment quickly after filing. The court's retained jurisdiction to enforce the agreement indicates a binding arrangement underpins the dismissal. The specific terms of the September 1, 2023 agreement are not disclosed in the available public record.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 67 days
67 days from filing to dismissal — notably swift resolution for a pharmaceutical patent infringement action
US7749532B2 & US8206740B2 — Once-Daily Tetracycline Formulations
Any pharmaceutical company, generic manufacturer, or CDMO developing once-daily tetracycline formulations — whether for dermatological, anti-infective, or other indications — should assess freedom to operate against these two patents before ANDA submission or commercial launch. The dismissal without prejudice in this case means neither patent was invalidated or found unenforceable, and Galderma retains full enforcement rights.
Official order — verbatim text
The stipulation dismissed all claims, counterclaims, and affirmative defenses without prejudice and without costs, pursuant to a September 1, 2023 agreement. The court's express retention of jurisdiction to enforce and resolve disputes under that agreement is a notable structural feature — it means the dismissal is not a clean severance but is tethered to the underlying arrangement. The specific terms of that arrangement are not disclosed in the available record.
Dismissed without prejudice: what the stipulated resolution means for both parties
Rule 41(a)(1)(A)(ii): stipulated dismissal without prejudice
A Rule 41(a)(1)(A)(ii) dismissal occurs when all parties who have appeared sign a stipulation of dismissal. 'Without prejudice' means the plaintiffs are not barred from re-filing the same claims in future. The court retained jurisdiction to enforce the underlying September 1, 2023 agreement — a feature typically associated with settlements, though the specific terms of that agreement are not disclosed in the available record.
Claims may be re-filedGalderma preserves future enforcement rights on both patents
Because the dismissal is without prejudice, Galderma Laboratories and TCD Royalty Sub retain the right to assert US7749532B2 and US8206740B2 against Dr. Reddy's or other parties in future proceedings. No adverse judgment was entered. The court's retained jurisdiction to enforce the agreement provides Galderma a mechanism to seek relief if the agreement is breached, without initiating entirely new litigation.
Patents remain enforceableDr. Reddy's avoids adverse judgment — but exposure remains open
Dr. Reddy's Laboratories (both entities) exits this proceeding without a finding of infringement or validity. No costs or attorneys' fees were awarded against them. However, the without-prejudice nature of the dismissal means the infringement claims could be re-filed. The parties are also bound by the September 1, 2023 agreement, and the court retains jurisdiction to resolve any disputes arising from it. The specific terms of that agreement are not disclosed in the available record.
No adverse finding enteredRetained jurisdiction signals a structured resolution in the tetracycline space
The combination of a rapid 67-day timeline, a without-prejudice dismissal, and expressly retained court jurisdiction is consistent with a commercially negotiated resolution in the pharmaceutical sector. For competitors and generic manufacturers operating in the once-daily tetracycline formulation space, the continued enforceability of US7749532B2 and US8206740B2 warrants FTO assessment. The specific commercial terms governing Dr. Reddy's position are not disclosed in the available record.
Both patents remain in forceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Galderma Laboratories | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Tcd Royalty Sub, LP | Company | Search in Eureka ↗ |
| Defendant | Dr. Reddy's Laboratories, Ltd. | Company | /Search in Eureka ↗ |
| Co-Defendant | Dr. Reddy's Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Galderma LaboratoriesSearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Galderma LaboratoriesSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Galderma LaboratoriesSearch in Eureka ↗ |
| Presiding judge | Judge Stephanos Bibas | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the once-daily tetracycline formulation space
Forward-looking patent and R&D intelligence derived from Galderma's and Dr. Reddy's IP activity in the tetracycline and pharmaceutical formulation domain.
Galderma's tetracycline and dermatology patent filing activity
Galderma holds two asserted patents in once-daily tetracycline formulations, with TCD Royalty Sub, LP as a co-plaintiff suggesting a broader royalty or licensing structure. Monitoring Galderma's continuation and divisional filings around these applications can reveal whether the portfolio is being actively extended — a signal of ongoing exclusivity strategy in this formulation space.
Galderma tetracycline portfolioFiling trends in controlled-release tetracycline formulation IP
Once-daily tetracycline formulations require controlled-release technology to sustain therapeutic plasma levels. Patent filing trends in this space — covering release polymers, coating technologies, and bioavailability-enhancing excipients — can identify where innovation is occurring and which players are building blocking positions around Galderma's core claims.
Controlled-release tetracycline trendsDr. Reddy's patent activity in pharmaceutical formulations
Dr. Reddy's Laboratories is a major generic pharmaceutical manufacturer with an active IP portfolio in drug formulation technologies. Tracking their patent filings in the tetracycline and antibiotic formulation space can reveal whether they are pursuing design-around strategies or investing in proprietary formulation technologies that may compete with or differentiate from Galderma's patented once-daily approach.
Dr. Reddy's formulation IPAdjacent IP white-space near once-daily tetracycline claims
The claim scope of US7749532B2 and US8206740B2 centres on specific once-daily tetracycline formulations. Adjacent white-space may exist in alternative dosing regimens, novel tetracycline derivatives, combination formulations, or topical delivery systems — areas where new filings could avoid the core claim scope while capturing differentiated therapeutic utility.
Tetracycline formulation white-spaceSimilar pharmaceutical patent cases in Delaware District Court
Cases involving pharmaceutical formulation patents and generic manufacturer defendants in the Delaware District Court, including once-daily dosage and tetracycline-related disputes.
What this case signals for the pharmaceutical tetracycline IP landscape
A 67-day lifecycle and retained court jurisdiction point to structured deal-making behind the dismissal — with both patents still live.
Without-prejudice dismissal keeps Galderma's enforcement options fully open
Neither US7749532B2 nor US8206740B2 was adjudicated on the merits. Galderma and TCD Royalty Sub can re-assert these patents against Dr. Reddy's or any other generic entrant. Competitors in the once-daily tetracycline formulation space should treat these patents as active enforcement risk, not resolved.
Court's retained jurisdiction is a key structural signal for the sector
Delaware federal courts retaining jurisdiction post-dismissal is a strong indicator of an underlying agreement with ongoing obligations. Other generic manufacturers considering ANDA filings or market entry in this space should factor in the possibility of structured licensing or access arrangements that may affect competitive dynamics — though the specific terms are not public.
Galderma v Dr. — key questions answered
Galderma Laboratories and TCD Royalty Sub, LP asserted two patents: US7749532B2 (application US10/819620) and US8206740B2 (application US12/155676), both directed to once-daily formulations of tetracyclines. The case was filed in the U.S. District Court for the District of Delaware on June 30, 2023.
The parties stipulated under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) to dismiss all claims without prejudice, pursuant to an agreement dated September 1, 2023. The specific terms of that agreement are not disclosed in the available public record. No costs, disbursements, or attorneys' fees were awarded to any party.
No. A dismissal without prejudice does not constitute an adjudication on the merits. US7749532B2 and US8206740B2 were neither invalidated nor found unenforceable. Galderma and TCD Royalty Sub retain full rights to assert these patents in future proceedings against Dr. Reddy's or other parties.
The stipulation expressly provides that the U.S. District Court for the District of Delaware retains jurisdiction to enforce and resolve disputes arising under the September 1, 2023 agreement. This means that if either party alleges a breach of that agreement, they can seek relief in the same court without initiating an entirely new lawsuit. The specific terms of the agreement are not in the public record.
TCD Royalty Sub, LP is a co-plaintiff alongside Galderma Laboratories, L.P. in this infringement action. Its presence as a party-plaintiff is consistent with a royalty or licensing arrangement involving ownership or beneficial interest in the asserted patents. The specific nature of TCD Royalty Sub's interest in US7749532B2 and US8206740B2 is not detailed in the available case record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.